Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity (Q35851815)

10 August 2017

1 reference

title

Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity (English)

1 reference

10 August 2017

2

1 reference

10 August 2017

Beatrice H Hahn

5

0 references

Barton Haynes

series ordinal

6

object named as

Barton F Haynes

1 reference

10 August 2017

4

Hua-Xin Liao

1 reference

10 August 2017

Feng Gao

1

1 reference

PubMed ID

15285714

10 August 2017

Eric Weaver

series ordinal

3

1 reference

10 August 2017

1 August 2004

1 reference

Expert Review of Vaccines

10 August 2017

1 reference

10 August 2017

3

1 reference

10 August 2017

S161-8

1 reference

10 August 2017

4 Suppl

1 reference

HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women

10 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Immune control of HIV: the obstacles of HLA and viral diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Diversity considerations in HIV-1 vaccine selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Generation of a consensus sequence from prevalent and incident HIV-1 infections in West Africa to guide AIDS vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Unprecedented degree of human immunodeficiency virus type 1 (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Detection of HIV-1 subtypes, recombinants, and dual infections in east Africa by a multi-region hybridization assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

High proportion of unrelated HIV-1 intersubtype recombinants in the Mbeya region of southwest Tanzania

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

HIV-1 nomenclature proposal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Immunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

HIV vaccine design and the neutralizing antibody problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Timing the ancestor of the HIV-1 pandemic strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

HIV vaccines: where we are and where we are going

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S161

10.1586/14760584.3.4.S161

21 January 2018

Identifiers

DOI

1 reference

release_66k4hkoyr5axlhpsmhgymwrg2m

10 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/66k4hkoyr5axlhpsmhgymwrg2m

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

15285714

1 reference

PubMed ID

15285714